Gapping down
In reaction to disappointing earnings/guidance: SCTY -19.3%, MNKD -18.2%, BIOL -13.7%, GPS -11.7%, BLOX -11.4%, FRGI -10.9%, VSLR -9.7%, SEDG -9%, LL -8.9%, SSNI -8.4%, GEN -7.9%, NVCR -7.9%, ZBRA -7.3%, VVC -6.7%, CFRX -6.4%, AAOI -6.3%, NCLH -6.2%, BDSI -6%, RBC -6%, BIOD -5.8%, INVN -5.5%, AMID -5.4%, GNK -5.2%, INGN -5.1%, ARLZ -5%, PLUG -4.7%, EZPW -3.8%, LSCC -3.7%, GLOB -3.5%, ACM -3.4%, NOK -3.3%, CVU -3%, NOK -2.8%, CS -2.8%, ARIA -2.8%, BKD -1.7%, RAX -1.5%, HK -1.4%, BSM -1.2%, EVEP -0.8%, FSC -0.8%, KNDI -0.7%
Other news: NLNK -34.8% (results of its Phase 3 clinical trial for algenpantucel-L for patients with resected pancreatic cancer did not achieve primary endpoint, also reported earnings), TSE -5.7% (Bain Capital Everest Manager to sell 8 mln ordinary shares pursuant to shelf registration), LC -2.8% (The SEC will review LendingClub's disclosures following today's announced irregularities, according to Bloomberg), ZTS -2.1% (Bill Ackman's Pershing Square is selling nearly 17 mln shares of Zoetis, according to the NYTimes), VRX -1.9% (continued volatility in pre-mkt trade), ED -1.7% (to commence registered underwritten public offering of 8.8 mln common shares)
Analyst comments: SFM -2.7% (downgraded to Sell from Neutral at Goldman), CHKP -1% (downgraded to Neutral from Buy at Citigroup), JD -0.9% (downgraded to Neutral from Outperform at Credit Suisse), AFL -0.8% (downgraded to Mkt Perform from Outperform at FBR Capital)
In reaction to disappointing earnings/guidance: SCTY -19.3%, MNKD -18.2%, BIOL -13.7%, GPS -11.7%, BLOX -11.4%, FRGI -10.9%, VSLR -9.7%, SEDG -9%, LL -8.9%, SSNI -8.4%, GEN -7.9%, NVCR -7.9%, ZBRA -7.3%, VVC -6.7%, CFRX -6.4%, AAOI -6.3%, NCLH -6.2%, BDSI -6%, RBC -6%, BIOD -5.8%, INVN -5.5%, AMID -5.4%, GNK -5.2%, INGN -5.1%, ARLZ -5%, PLUG -4.7%, EZPW -3.8%, LSCC -3.7%, GLOB -3.5%, ACM -3.4%, NOK -3.3%, CVU -3%, NOK -2.8%, CS -2.8%, ARIA -2.8%, BKD -1.7%, RAX -1.5%, HK -1.4%, BSM -1.2%, EVEP -0.8%, FSC -0.8%, KNDI -0.7%
Other news: NLNK -34.8% (results of its Phase 3 clinical trial for algenpantucel-L for patients with resected pancreatic cancer did not achieve primary endpoint, also reported earnings), TSE -5.7% (Bain Capital Everest Manager to sell 8 mln ordinary shares pursuant to shelf registration), LC -2.8% (The SEC will review LendingClub's disclosures following today's announced irregularities, according to Bloomberg), ZTS -2.1% (Bill Ackman's Pershing Square is selling nearly 17 mln shares of Zoetis, according to the NYTimes), VRX -1.9% (continued volatility in pre-mkt trade), ED -1.7% (to commence registered underwritten public offering of 8.8 mln common shares)
Analyst comments: SFM -2.7% (downgraded to Sell from Neutral at Goldman), CHKP -1% (downgraded to Neutral from Buy at Citigroup), JD -0.9% (downgraded to Neutral from Outperform at Credit Suisse), AFL -0.8% (downgraded to Mkt Perform from Outperform at FBR Capital)